![conference banner](/images/conference-banner.jpeg)
Abstract
L-asparaginase (L-asparagine amino hydrolase, E.C.3.5.1.1) is the most important chemotherapeutic drug used in treating Acute Lymphocytic Leukemia (ALL), decreasing blood asparagine rates causing apoptosis in tumor cells. However, pharmacological drugs cause several side effects making treatments difficult. Thus, searches for new sources of L-asparaginase or enzyme modifications focus on discovering new products to use in therapy. This article reviewed published patents from 2000 to 2020 related to the treatment of ALL using L-asparaginase. Many organisms have been shown as potential viable L-asparaginase producers for use in the treatment of ALL. However, this patent review shows that few of these organisms are gaining attention to becoming bioproducts for the market. It is expected that drugs in the testing phase and patents related to the treatment of ALL and other cancers will become real products. Besides, a treatment using an amino acid depletion approach, now referring to asparagine, altogether with a compound that directly interferes with the expression of the asparagine synthase gene, is more suitable for the treatment of ALL and possibly to other cancers.
Keywords: Acute lymphocytic leukemia, cancer, enzyme, improvement, L-asparaginase, patent, treatment, products.
Recent Advances in Drug Delivery and Formulation
Title:A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia
Volume: 15 Issue: 1
Author(s): Davi Almeida Freire*, Ilana Carneiro Lisboa Magalháes, Eridan Orlando Pereira Tramontina Florean and Maria Izabel Florindo Guedes
Affiliation:
- Department of Biotechnology, Universidade Estadual do Ceará, Fortaleza,Brazil
Keywords: Acute lymphocytic leukemia, cancer, enzyme, improvement, L-asparaginase, patent, treatment, products.
Abstract: L-asparaginase (L-asparagine amino hydrolase, E.C.3.5.1.1) is the most important chemotherapeutic drug used in treating Acute Lymphocytic Leukemia (ALL), decreasing blood asparagine rates causing apoptosis in tumor cells. However, pharmacological drugs cause several side effects making treatments difficult. Thus, searches for new sources of L-asparaginase or enzyme modifications focus on discovering new products to use in therapy. This article reviewed published patents from 2000 to 2020 related to the treatment of ALL using L-asparaginase. Many organisms have been shown as potential viable L-asparaginase producers for use in the treatment of ALL. However, this patent review shows that few of these organisms are gaining attention to becoming bioproducts for the market. It is expected that drugs in the testing phase and patents related to the treatment of ALL and other cancers will become real products. Besides, a treatment using an amino acid depletion approach, now referring to asparagine, altogether with a compound that directly interferes with the expression of the asparagine synthase gene, is more suitable for the treatment of ALL and possibly to other cancers.
Export Options
About this article
Cite this article as:
Freire Almeida Davi *, Lisboa Magalháes Carneiro Ilana , Tramontina Florean Orlando Pereira Eridan and Florindo Guedes Izabel Maria , A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia, Recent Advances in Drug Delivery and Formulation 2021; 15 (1) . https://dx.doi.org/10.2174/1872211314666210301125843
DOI https://dx.doi.org/10.2174/1872211314666210301125843 |
Print ISSN 2667-3878 |
Publisher Name Bentham Science Publisher |
Online ISSN 2667-3886 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets The Potential Roles of Magnetic Resonance Spectroscopy and Perfusion- Weighted Imaging in the Grading of Cerebral Gliomas
Current Medical Imaging Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope
Reviews on Recent Clinical Trials Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Focusing the Controversies in Budd-Chiari Syndrome Management
The International Journal of Gastroenterology and Hepatology Diseases The Antinflammatory Effect of Alpha-MSH in Skin: A Promise for New Treatment Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular and Molecular Regulation of Inflammatory Pain, Nociception and Hyperalgesia - The Role of the Transcription Factor NF-κB as the Lynchpin Nocisensor: Hyperalgesic or Analgesic Effect?
Current Immunology Reviews (Discontinued) Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry Pancreatic Cancer Surgery: The State of the Art
Current Drug Targets CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times
Recent Patents on Biotechnology Neurotransplantation Therapy and Cerebellar Reserve
CNS & Neurological Disorders - Drug Targets ATP Synthase: A Molecular Therapeutic Drug Target for Antimicrobial and Antitumor Peptides
Current Medicinal Chemistry Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia
Endocrine, Metabolic & Immune Disorders - Drug Targets Antibody-Drug Conjugate Targets
Current Cancer Drug Targets